ArticleDiscover oncology2025
Global research landscapes of ALDH2 and cancer revealed by bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative multi-omics analysis prioritizes ALDH2 as a candidate Puerarin-associated target linked to macrophage infiltration in lung adenocarcinoma.Frontiers in immunology · 2026Article
- Global, regional, and national burden of lip and oral cavity cancer attributable to smoking, 1990-2021: A secondary dataset analysis of GBD 2021.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Recent years have seen a marked increase in studies focusing on the mechanistic role of Aldehyde dehydrogenase 2 (ALDH2) genetic polymorphisms in tumors, yet this field lacks systematic bibliometric analysis. By analyzing publication years, countries/regions, research institutions, disciplinary domains, authorship networks, journal distributions, and keyword networks, this study reveals that global research interest in ALDH2 and tumors continues to rise. China, the United States, and Japan form the core contributing triangle, with institutions such as Aichi Cancer Center and Stanford University leading cutting-edge exploration. The research landscape concentrates on oncology, biochemistry and molecular biology, and cell biology, while interdisciplinary immunology provides innovative perspectives. Key future directions include elucidating the regulatory networks of ALDH2 polymorphisms in the metabolism-cancer axis and their associations with gastrointestinal and hematologic malignancies, alongside mechanistic studies encompassing oxidative stress modulation, ferroptosis regulation, DNA adduct formation, apoptotic cascades, DNA methylation, senescence-associated secretory phenotypes and tumor immune escape microenvironment dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.